CA3059453A1 - Methods for the treatment of inflammation and inflammatory conditions - Google Patents

Methods for the treatment of inflammation and inflammatory conditions Download PDF

Info

Publication number
CA3059453A1
CA3059453A1 CA3059453A CA3059453A CA3059453A1 CA 3059453 A1 CA3059453 A1 CA 3059453A1 CA 3059453 A CA3059453 A CA 3059453A CA 3059453 A CA3059453 A CA 3059453A CA 3059453 A1 CA3059453 A1 CA 3059453A1
Authority
CA
Canada
Prior art keywords
lactobacillus
strains
subject
cultured
cell free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3059453A
Other languages
English (en)
French (fr)
Inventor
Wayne FINLAYSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Servatus Ltd
Original Assignee
Servatus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901320A external-priority patent/AU2017901320A0/en
Application filed by Servatus Ltd filed Critical Servatus Ltd
Publication of CA3059453A1 publication Critical patent/CA3059453A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3059453A 2017-04-11 2018-04-11 Methods for the treatment of inflammation and inflammatory conditions Pending CA3059453A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017901320A AU2017901320A0 (en) 2017-04-11 Methods for the treatment of inflammation and inflammatory conditions
AU2017901320 2017-04-11
AU2017902271A AU2017902271A0 (en) 2017-06-15 Methods for the treatment of inflammation and inflammatory conditions
AU2017902271 2017-06-15
PCT/AU2018/050326 WO2018187838A1 (en) 2017-04-11 2018-04-11 Methods for the treatment of inflammation and inflammatory conditions

Publications (1)

Publication Number Publication Date
CA3059453A1 true CA3059453A1 (en) 2018-10-18

Family

ID=63792160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3059453A Pending CA3059453A1 (en) 2017-04-11 2018-04-11 Methods for the treatment of inflammation and inflammatory conditions

Country Status (8)

Country Link
US (2) US20200376047A1 (https=)
EP (1) EP3609515A4 (https=)
JP (1) JP7494110B2 (https=)
CN (1) CN110753553A (https=)
AU (1) AU2018251616B2 (https=)
CA (1) CA3059453A1 (https=)
SG (1) SG11201908857QA (https=)
WO (1) WO2018187838A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109172613B (zh) * 2018-08-14 2022-04-22 景岳生物科技(中国)有限公司 含乳杆菌死菌培养物的皮肤外用组合物及其于促进伤口愈合及降低疤痕产生的用途
CN114206362A (zh) * 2018-10-10 2022-03-18 赛瓦图斯有限公司 炎性状况和相关感染的治疗方法
GB201905386D0 (en) * 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
EP3815700A1 (en) * 2019-10-30 2021-05-05 Biomillenia SAS Medical compositions and their use in treating inflammatory bowel disease
US12329181B2 (en) * 2020-02-28 2025-06-17 Terragen Holdings Limited Microbial feed supplement composition and method
WO2021195703A1 (en) * 2020-03-31 2021-10-07 Servatus Ltd Combination therapy for inflammatory bowel disease
CN111733110B (zh) * 2020-07-17 2021-10-22 佛山市朗芯生物科技有限公司 副干酪乳杆菌及其在制备治疗溃疡性结肠炎药物中的应用
CN114470007B (zh) * 2020-11-13 2024-10-18 葡萄王生技股份有限公司 含乳酸菌发酵产物之皮肤创伤外用组合物及其用途
EP4255456A4 (en) * 2020-12-01 2024-09-25 Servatus Ltd METHODS TO IMPROVE SLEEP QUALITY
US20240033309A1 (en) * 2020-12-09 2024-02-01 Servatus Ltd Combination therapy for inflammatory disorders of the joints
CN112522160B (zh) * 2020-12-24 2022-05-10 广东省科学院微生物研究所(广东省微生物分析检测中心) 一株具有抗病毒能力的发酵乳杆菌pv22及其应用
KR102268128B1 (ko) * 2021-02-09 2021-06-22 주식회사 락토메이슨 모유 유래 신규한 락토바실러스 루테리 lm1071 균주, 및 상기 균주 또는 이의 배양물을 포함하는 월경전 증후군 완화용 조성물
CN114456967B (zh) * 2021-10-14 2022-10-04 命之源(杭州)生物科技有限公司 一种酵母、乳酸菌联合菌、培育方法及其应用
US20250057897A1 (en) * 2021-12-02 2025-02-20 Servatus Ltd Methods for the Treatment of Constipation
KR102879081B1 (ko) * 2023-03-28 2025-11-05 제이에스바이오컴퍼니 주식회사 락토바실러스 파카라제이 및 락토바실러스 부크네리를 포함하는 유산균 배양액 제조 방법 및 이를 이용한 피부 개선 기능성 원료 제조 방법
WO2025054048A1 (en) * 2023-09-08 2025-03-13 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating lipid and cholesterol metabolism associated diseases, disorders, and conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0114400B8 (pt) * 2000-10-06 2021-05-25 Nestle Sa uso de bactéria de ácido lático probiótica para equilibrar o sistema imunológico da pele
US20030175305A1 (en) 2002-01-08 2003-09-18 Garner Bryan E. Compositions and methods for inhibiting pathogenic growth
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
AU2013201442B2 (en) * 2005-09-28 2014-10-30 Nordic Rebalance A/S Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors
RU2009125184A (ru) * 2006-12-01 2011-01-10 Органобэлэнс Гмбх (De) Композиции, наборы и их применения для защиты кожи от патогенных микроорганизмов
KR100858840B1 (ko) 2007-03-05 2008-09-17 (주)네오팜 신규 유산균 균주 및 이를 포함하는 유산균 제제
US20110002994A1 (en) * 2007-10-02 2011-01-06 Institut National De La Recherche Scientifique Method of regulating the th17 pathway and its associated metabolic impact
WO2012039615A2 (en) * 2010-09-21 2012-03-29 Winclove Bio Industries B.V. Commensal rat ileum bacterium (crib)
US20140147427A1 (en) 2011-06-08 2014-05-29 Organobalance Gmbh Spray-Dried Lactobacillus Stems/Cells and the Use of Same Against Helicobacter Pylori
WO2013063658A1 (en) 2011-11-04 2013-05-10 International Marketing Partnerships Pty Ltd Microbial inoculants and fertilizer compositions comprising the same
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
NZ630117A (en) 2013-04-23 2017-09-29 Terragen Holdings Ltd Bacterial strains having antimicrobial activity and biocontrol compositions comprising the same
AR101538A1 (es) 2014-09-25 2016-12-28 Terragen Holdings Ltd Cepas bacterianas que tienen actividad antimicrobiana y composiciones de biocontrol que las comprenden

Also Published As

Publication number Publication date
EP3609515A4 (en) 2020-11-04
AU2018251616B2 (en) 2025-04-03
US20250032563A1 (en) 2025-01-30
US20200376047A1 (en) 2020-12-03
WO2018187838A1 (en) 2018-10-18
CN110753553A (zh) 2020-02-04
EP3609515A1 (en) 2020-02-19
JP7494110B2 (ja) 2024-06-03
JP2020516684A (ja) 2020-06-11
SG11201908857QA (en) 2019-10-30
AU2018251616A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
US20250032563A1 (en) Methods for the treatment of inflammation and inflammatory conditions
US20210338749A1 (en) Methods of treatment of inflammatory conditions and associated infections
JP6429131B2 (ja) 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用
CN106255504A (zh) 含有槲皮素糖苷的肌肉萎缩抑制剂
KR20190118985A (ko) 비만의 예방 또는 치료 효과를 가지는 신규 비피도박테리움 롱검 균주 또는 락토바실러스 람노서스 균주 및 이의 용도
US10723751B2 (en) Compositions and methods for treating infectious disease
JP7379152B2 (ja) 筋線維化抑制用組成物
US20230149481A1 (en) Combination therapy for inflammatory bowel disease
US20240033309A1 (en) Combination therapy for inflammatory disorders of the joints
JP2023526043A (ja) 細菌株を含む組成物、ならびに眼の疾患および病変の処置のための同組成物の使用
JP7626713B2 (ja) コンドロイチン硫酸合成促進用組成物
US20200405783A1 (en) Probiotic for the treatment of psoriasis
Coetzer OTC treatment of the side effects of antibiotics: OTC management

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220920

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20250218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250225

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250408

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250408